Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Silent myocardial ischemia.

S C Hammill1, B K Khandheria

  • 1Division of Cardiovascular Diseases and Internal Medicine, Mayo Clinic, Rochester, MN.

Mayo Clinic Proceedings
|March 1, 1990
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Valvular regurgitation and stenosis: when is surgery required?

Heart Asia·2016
Same author

Effect of cardiac resynchronisation therapy on occurrence of ventricular arrhythmia in patients with implantable cardioverter defibrillators undergoing upgrade to cardiac resynchronisation therapy devices.

Heart (British Cardiac Society)·2007
Same author

Established and evolving indications for cardiac resynchronisation.

Heart (British Cardiac Society)·2004
Same author

Role of programmed ventricular stimulation and implantable cardioverter defibrillators in patients with idiopathic dilated cardiomyopathy and syncope.

Pacing and clinical electrophysiology : PACE·2002
Same author

American College of Cardiology key data elements and definitions for measuring the clinical management and outcomes of patients with acute coronary syndromes. A report of the American College of Cardiology Task Force on Clinical Data Standards (Acute Coronary Syndromes Writing Committee).

Journal of the American College of Cardiology·2001
Same author

Thromboembolic complications after electrical cardioversion in patients with atrial flutter.

The American journal of medicine·2001
Same journal

Advancing Pulmonary Fibrosis Care: Integrating Genomic Insights Into Clinical Practice.

Mayo Clinic proceedings·2026
Same journal

RAAS Inhibition in the ICU: Stop, Continue, or Restart?

Mayo Clinic proceedings·2026
Same journal

Chronic Kidney Disease-In the Limelight, July 2026.

Mayo Clinic proceedings·2026
Same journal

In Reply: Long-Term Cardiovascular Burden After Carotid Endarterectomy: Moving Beyond Conventional Risk Profiling.

Mayo Clinic proceedings·2026
Same journal

Long-Term Cardiovascular Burden After Carotid Endarterectomy: Moving Beyond Conventional Risk Profiling.

Mayo Clinic proceedings·2026
Same journal

Real-World Comparative Effectiveness of Tirzepatide and Semaglutide for Obesity: A Multicentered Study.

Mayo Clinic proceedings·2026
See all related articles

Silent ischemia, indicated by ST-segment depression without symptoms, is a significant marker for coronary artery disease. Reducing this silent ischemia may improve patient outcomes, though further proof is needed.

Area of Science:

  • Cardiology
  • Ischemic Heart Disease

Background:

  • ST-segment depression without symptoms is a recognized abnormality in coronary artery disease patients.
  • This silent ischemia signifies myocardial perfusion defects and is a key indicator of cardiac events.

Purpose of the Study:

  • To highlight the prognostic importance of silent ischemia in coronary artery disease.
  • To discuss the concept of total ischemic burden and its potential modification.

Main Methods:

  • Utilized 24-hour ambulatory ECG monitoring to detect episodes of ST-segment depression.
  • Analyzed the occurrence of silent ischemia in relation to heart rate and symptoms.

Main Results:

  • Most ischemic episodes in coronary artery disease patients are silent, occurring at normal heart rates.

Related Experiment Videos

  • Silent ischemia, combined with angina-related ischemia, defines total ischemic burden.

    • Conclusions:

    • Silent ischemia is a critical prognostic marker for future myocardial events.
    • Standard antianginal therapy can reduce silent ischemia and total ischemic burden, potentially improving patient outcomes.